Connectome-mediated prediction of future tau-PET burden in Alzheimer's disease
Pablo F. Damasceno,
Renaud La Joie,
Ixavier A. Higgins,
Gil D. Rabinovici,
Mark A Mintun,
Posted 12 Aug 2020
bioRxiv DOI: 10.1101/2020.08.11.246496
Posted 12 Aug 2020
Alzheimer's Disease (AD) tau pathology originates in the brainstem and subsequently spreads to the entorhinal cortex, hippocampus and finally to temporal, parietal and prefrontal association cortices in a relatively stereotyped progression. Current evidence attributes this orderly progression to trans-neuronal spread of misfolded tau protein along the projection pathways of affected neurons. The aggregation of tau is being increasingly recognized as a trustworthy biomarker preceding the appearance of Alzheimer's disease (AD) symptoms. One major goals of disease modifying therapies has been to stop or slow down the tau aggregation process. In order to evaluate drug efficacy, it would be desirable to have an accurate model predictive of a patient's future tau burden, against which the tau measurements from drug-receiving cohorts could be compared. Here we report the development of such a model, evaluated in a cohort of 88 subjects clinically diagnosed as Mild Cognitively Impaired (MCI = 60) or Alzheimer's disease (AD = 28) and tracked over a period of 18 months. Our approach combined data-driven and model-based methodologies, with the goal of predicting changes in tau within suitably specified target regions. We show that traditional statistical methods, allied to a network diffusion model for tau propagation in the brain, provide a remarkable prediction of the magnitude of incremental tau deposited in particular cortical areas of the brain over this period (MCI: R2 = 0.65+-0.16; AD: R2 = 0.71+-0.11) from baseline data. Our work has the potential to greatly strengthen the repertoire of analysis tools used in AD clinical trials, opening the door to future interventional trials with far fewer sample sizes than currently required. ### Competing Interest Statement PFD, RLJ, AR have no interests to declare. SS, SS, VK, IH, EC, MM are employees of Eli Lilly and Company. GR is Study Chair for the IDEAS study; Additional research support from National Institutes of Health (NIH), Alzheimer's Association, Tau Consortium, Avid Radiopharmaceuticals, and Eli Lilly. Consultant for Axon Neurosciences, General Electric (GE) Healthcare, Eisai, Merck. Associate Editor for JAMA Neurology.
- Downloaded 90 times
- Download rankings, all-time:
- Site-wide: 91,408 out of 100,334
- In neuroscience: 16,363 out of 17,859
- Year to date:
- Site-wide: 58,856 out of 100,334
- Since beginning of last month:
- Site-wide: 8,972 out of 100,334
Downloads over time
Distribution of downloads per paper, site-wide
- 20 Oct 2020: Support for sorting preprints using Twitter activity has been removed, at least temporarily, until a new source of social media activity data becomes available.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!